BR0008057A - Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada - Google Patents

Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada

Info

Publication number
BR0008057A
BR0008057A BR0008057-8A BR0008057A BR0008057A BR 0008057 A BR0008057 A BR 0008057A BR 0008057 A BR0008057 A BR 0008057A BR 0008057 A BR0008057 A BR 0008057A
Authority
BR
Brazil
Prior art keywords
eplerenone
crystalline form
preparing
crystalline
dissolution rate
Prior art date
Application number
BR0008057-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Kathleen Barton
Thomas B Borchardt
Marlon V Carlos
Subhash Desai
Leonard J Ferro
Henry T Gaud
Scott Ganser
Clay R Little
Partha S Mudipalli
Mark A Pietz
Daniel R Pilipauskas
Yuen-Lung L Sing
Glenn L Stahl
Joseph J Wieczorek
Chris Y Yan
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0008057A publication Critical patent/BR0008057A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR0008057-8A 1999-12-08 2000-12-04 Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada BR0008057A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16969099P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
PCT/US2000/032416 WO2001042272A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Publications (1)

Publication Number Publication Date
BR0008057A true BR0008057A (pt) 2002-04-23

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008057-8A BR0008057A (pt) 1999-12-08 2000-12-04 Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada

Country Status (18)

Country Link
EP (1) EP1177204A2 (zh)
JP (1) JP2003516414A (zh)
KR (1) KR100607923B1 (zh)
CN (2) CN1557833A (zh)
AU (1) AU784946B2 (zh)
BR (1) BR0008057A (zh)
CA (1) CA2362669A1 (zh)
CO (1) CO5280211A1 (zh)
EA (1) EA007934B1 (zh)
HK (1) HK1050536A1 (zh)
HU (1) HUP0203032A3 (zh)
IL (3) IL144764A0 (zh)
MX (1) MXPA01008056A (zh)
MY (1) MY131878A (zh)
NO (1) NO20013856L (zh)
NZ (2) NZ530028A (zh)
PE (1) PE20010917A1 (zh)
WO (1) WO2001042272A2 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225871A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
ES2293944T3 (es) * 1996-12-11 2008-04-01 G.D. Searle Llc. Procedimiento de epoxidacion.
PT1165136E (pt) * 1999-03-05 2004-02-27 Searle Llc Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular

Also Published As

Publication number Publication date
IL176511A (en) 2007-08-19
AU784946B2 (en) 2006-08-03
WO2001042272A2 (en) 2001-06-14
NO20013856L (no) 2001-10-08
CA2362669A1 (en) 2001-06-14
EA200100871A1 (ru) 2002-04-25
HUP0203032A2 (hu) 2002-12-28
PE20010917A1 (es) 2001-09-10
HUP0203032A3 (en) 2003-04-28
WO2001042272A9 (en) 2002-12-12
JP2003516414A (ja) 2003-05-13
KR20010112261A (ko) 2001-12-20
NO20013856D0 (no) 2001-08-08
AU2049201A (en) 2001-06-18
CN1377365A (zh) 2002-10-30
HK1050536A1 (en) 2003-06-27
MXPA01008056A (es) 2003-07-21
CO5280211A1 (es) 2003-05-30
CN1152886C (zh) 2004-06-09
NZ513961A (en) 2004-02-27
IL144764A0 (en) 2002-06-30
MY131878A (en) 2007-09-28
IL144764A (en) 2007-08-19
NZ530028A (en) 2005-08-26
KR100607923B1 (ko) 2006-08-04
CN1557833A (zh) 2004-12-29
EA007934B1 (ru) 2007-02-27
WO2001042272A3 (en) 2001-11-29
EP1177204A2 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0410786A (pt) composição, uso da mesma, e, método de tratamento de um distúrbio de humor em um paciente
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
KR920700033A (ko) 로라타딘, 이부프로펜 및 슈도에페드린을 함유하는 약제학적 조성물
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
BR0008058A (pt) Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
BRPI0117180B8 (pt) composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior
SE9804000D0 (sv) New composition of matter
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
RU2010107177A (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
BR9509478A (pt) Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0008054A (pt) Forma cristalina de eplerenona
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BRPI0408113A (pt) métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 12A E 13A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 12A, 13A, 14A, 15A, 16A, 17A, 18A E 19A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.